As of May 27
| +0.0044 / +1.07%|
The 3 analysts offering 12-month price forecasts for Peregrine Pharmaceuticals Inc have a median target of 1.00, with a high estimate of 1.50 and a low estimate of 0.50. The median estimate represents a +141.31% increase from the last price of 0.41.
The current consensus among 3 polled investment analysts is to Buy stock in Peregrine Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.